Stay updated on CDX-0159 in Eosinophilic Esophagitis Clinical Trial
Sign up to get notified when there's something new on the CDX-0159 in Eosinophilic Esophagitis Clinical Trial page.

Latest updates to the CDX-0159 in Eosinophilic Esophagitis Clinical Trial page
- Check3 days agoChange DetectedThe site revision marker changed from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check10 days agoChange DetectedThe ClinicalTrials.gov record for the Phase 2 barzolvolimab study in adults with eosinophilic esophagitis is displayed, with details on the study design, results measures, eligibility, and participating locations.SummaryDifference67%

- Check17 days agoChange DetectedThe site footer revision changes from v3.7.2 to v3.8.0, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check31 days agoChange DetectedA sitewide NIH notice about terminology during the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the site revision advances from v3.7.1 to v3.7.2. The study record itself still displays a 403 error.SummaryDifference1%

- Check45 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1. The page still displays a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check59 days agoChange DetectedThe study record now displays a 403 Forbidden error instead of the usual study details, removing access to the trial information, locations, and related data.SummaryDifference18%

Stay in the know with updates to CDX-0159 in Eosinophilic Esophagitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CDX-0159 in Eosinophilic Esophagitis Clinical Trial page.